Pfizer Sees Neurontin Exclusivity Through 2002, Pregabalin Filing By Year-End
Executive Summary
Pfizer expects at least 30 months of additional exclusivity for the epilepsy agent Neurontin (gabapentin) beyond the expiration of the basic compound patent July 15.
You may also be interested in...
Alpharma Generic Neurontin Approval Precedes FDA Reinspection
Approval of Alpharma's ANDA for a generic version of Pfizer's Neurontin (gabapentin) comes just ahead of FDA's expected reinspection of the Elizabeth, N.J. facility where gabapentin will be manufactured
Alpharma Generic Neurontin Approval Precedes FDA Reinspection
Approval of Alpharma's ANDA for a generic version of Pfizer's Neurontin (gabapentin) comes just ahead of FDA's expected reinspection of the Elizabeth, N.J. facility where gabapentin will be manufactured
Neurontin Bulk Supply May Limit Generic Uptake, Pfizer Says
Neurontin generics will have to overcome limitations in the bulk drug supply in addition to Pfizer's patent defenses, Pfizer CEO Henry McKinnell told a Jan. 22 earnings conference call